4 results
Compare Progression Free Survival (PFS) for brivanib versus placebo in subjects with advanced solid tumors with FGF-2 over-expression and who have obtained stable disease after 12 weeks of treatment with brivanib separately for each tumor.
Primary Objectives:• Assess the pharmacokinetic (PK) and pharmacodynamic (PD)/efficacy effects of 3 different single doses of EVP-6124 vs. placebo;• Assess the PK and PD/efficacy effects of the different combinations of 2 doses of donepezil and 3…
The aim of this study is to evaluate the dosimetry and toxicity of Lutetium-177-PSMA-617, in patients with low volume, hormone sensitive metastatic prostate cancer.
Primary objectivesPart 1To evaluate the single dose safety and tolerability of donepezil 10 mg when administered with placebo, glycopyrrolate or trospiumPart 2To evaluate the safety and tolerability of donepezil when given with concomitant placebo,…